文献速递核素与放射性配体治疗骨显像与常规 SPECT甲状腺核医学

靶向放射性核素治疗:历史与个人回顾

Targeted Radionuclide Therapy: A Historical and Personal Review.
PubMed 文献 · Semin Nucl Med · 2019-11-06

本综述追溯靶向放射性核素治疗(TRT)从天然放射性发现、人工放射性制备到当前临床实践的发展历程。文章回顾了碘放射性同位素用于控制甲状腺功能亢进及治疗分化型甲状腺癌的抗肿瘤效应,并延伸至131I-MIBG治疗恶性及转移性嗜铬细胞瘤和副神经节瘤、131I-托西莫单抗治疗CD20表达的非霍奇金淋巴瘤,以及90Y和177Lu标记生长抑素类似物治疗转移性神经内分泌肿瘤的演变。近年针对前列腺特异性膜抗原(PSMA)的靶向治疗正在评估中,223Ra作为α发射体用于骨转移去势抵抗性前列腺癌。

要点

  • 放射性碘最早用于研究甲状腺碘动力学,随后观察到足够辐射量可控制甲状腺功能亢进。
  • 放射性碘用于分化型甲状腺癌患者时观察到抗肿瘤效应,扩展了「魔法子弹」概念。
  • 90Y标记生长抑素类似物治疗转移性神经内分泌肿瘤,因物理特性更适合照射微转移灶而几乎被177Lu取代。

核心结论

  • 靶向放射性核素治疗从放射性碘起步,已扩展至131I-MIBG、131I-托西莫单抗、90Y/177Lu标记生长抑素类似物及PSMA靶向药物等多个方向。
  • 223Ra作为α发射体具有更强放射生物学效应但组织内射程有限,治疗骨髓转移时增加了安全性要素。

研究设计与样本

  • 本文为历史与个人回顾性综述,追溯靶向放射性核素治疗从天然放射性发现、人工放射性制备到当前医学文献与临床实践的发展。

主要发现

  • 放射性碘最初用于研究甲状腺碘动力学,随后观察到足够辐射量可控制甲状腺功能亢进。
  • 放射性碘用于分化型甲状腺癌患者时观察到抗肿瘤效应。
  • 131I-MIBG用于治疗恶性及转移性嗜铬细胞瘤和副神经节瘤。
  • 131I-托西莫单抗为放射性碘标记的抗CD20 IgG,用于治疗CD20表达的非霍奇金淋巴瘤。
  • 90Y最初用于放射性标记生长抑素类似物治疗转移性神经内分泌肿瘤,但因177Lu物理特性似乎更适合有效照射神经内分泌肿瘤微转移灶而几乎被177Lu取代。

关键数值与推荐

  • 抗PSMA免疫球蛋白(J591)和小分子谷氨酸配体目前正在作为靶向放射性核素治疗药物进行评估。
  • 对骨内羟基磷灰石具有亲和力的放射性核素用于缓解肿瘤转移所致骨痛,基于骨趋向性放射性金属在肿瘤转移灶与骨基质成骨界面的沉积增加。
  • 多数骨痛缓解试验在转移性前列腺癌患者中进行,因其他选择很少。
  • 其他α发射放射性金属目前正在评估作为替代90Y和177Lu的放射性金属来标记靶向分子。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This review traces the development of targeted radionuclide therapy (TRT) (the Magic Bullet) from the discovery of radioactivity in nature and the subsequent discovery of artificial radioactivity (the production of radioactive isotopes of stable elements) to the current status of TRT in the medical literature and clinical practice. With the availability of radioisotopes of iodine, initially to study thyroidal iodine kinetics, it was soon observed that sufficient amounts of radiation could control thyroid hyperfunction. Shortly thereafter, when radioiodine was administered to a patient with differentiated thyroid carcinoma whose hypermetabolism was secondary to excess thyroid hormone production, it was observed that radioiodine also had an antitumor effect. The concept of the Magic Bullet has since been extended to other disease states such as (1) 131I-meta-iodobenzylguanidine (131I-MIBG) to treat malignant and metastatic pheochromocytomas and paragangliomas; (2) 131I-tositumomab, a radioiodinated anti-CD20 IgG to treat CD20 expressing non-Hodgkins lymphoma. In recent years, other β-emitting radionuclides, Yttrium-90 (90Y) and Lutetium-177 (177Lu), have been added to this list. These radiometals have different physical properties that were thought to be possibly more effective than radioiodine. 90Y was initially used to radio-label somatostatin analogues to treat metastatic neuroendocrine tumors but has virtually been replaced by 177Lu since the physical characteristics of the latter appear to be better suited to effectively irradiate the micrometastases of neuroendocrine tumors. A similar evolution is taking place in the development of a targeted radionuclide therapeutic that recognizes prostate-specific membrane antigen (PSMA), an epitope expressed in increased amounts in prostate carcinoma. Both an anti-PSMA immunoglobulin (J591) and a small molecule glutamase ligand are currently being evaluated as targeted radionuclide therapy agents. Radionuclides that have affinity for the calcium hydroxyapatite in bone have been used to relieve bone pain due to tumor metastases based on increased deposition of the bone seeking radiometals at the osteoblastic interface of the tumor metastases and boney matrix. Most of these trials have been in patients with metastatic prostate cancer since there are few other options. In this regard, targeted radionuclide therapy has come full circles as the most recent addition to this anti-tumor arsenal is a radioisotope of Radium, 223Ra, an alpha emitter which has a greater radiobiologic effect but limited range in tissue thus adding an element of safety when treating marrow metastases. Other alpha emitting radiometals are currently being evaluated as alternative radiometals in place of 90Y and 177Lu to label targeting molecules.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Goldsmith SJ. Targeted Radionuclide Therapy: A Historical and Personal Review. Semin Nucl Med. 2019. PMID: 31843064. doi:10.1053/j.semnuclmed.2019.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。